News
11hon MSN
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
28m
Capital Market on MSNAstraZeneca Pharma slides as MD Sanjeev Panchal steps down; Praveen Rao Akkinepally to take chargePanchal is set to transition to a global role within the AstraZeneca Group, based in Gaithersburg, Maryland, US. The board ...
Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.
21h
GlobalData on MSNEC approves AstraZeneca’s acalabrutinib combo for CLLThe EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.
Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...
Bangalore: AstraZeneca Pharma India has announced the appointment of Praveen Rao Akkinepally as the new Managing Director of ...
AstraZeneca, a major pharmaceutical company, has sued Utah’s Attorney General Derek Brown over a recently passed state law ...
AstraZeneca PLC closed 19.58% short of its 52-week high of £133.88, which the company reached on September 3rd.
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results